This technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells. Their ability to differentiate into various central nervous system cell types is vital for understanding NPC's underlying causes. Additionally, these NSCs are uniquely positioned for high-throughput drug screening, with the potential to identify novel compounds for treating NPC. This technology is particularly groundbreaking as it represents the first reported NSC line from an NPC patient, offering significant opportunities for novel discoveries in the disease's study.